Lineage Cell Therapeutics
LCTX
LCTX
107 hedge funds and large institutions have $113M invested in Lineage Cell Therapeutics in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 33 increasing their positions, 21 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less funds holding
Funds holding: →
25% less capital invested
Capital invested by funds: $152M → $113M (-$38.5M)
34% less call options, than puts
Call options by funds: $109K | Put options by funds: $164K
47% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 17
Holders
107
Holding in Top 10
2
Calls
$109K
Puts
$164K
Top Buyers
| 1 | +$1.19M | |
| 2 | +$498K | |
| 3 | +$373K | |
| 4 |
Two Sigma Investments
New York
|
+$132K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$111K |
Top Sellers
| 1 | -$1.42M | |
| 2 | -$1.3M | |
| 3 | -$899K | |
| 4 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$747K |
| 5 |
LCM
Laurion Capital Management
New York
|
-$472K |